Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor

Yavuz M. Bilgin; Otto J Visser; Erik A M Beckers; Liane CJ Te Boome; Cynthia Huisman; Paula F. Ypma; Alexandra J. Croockewit; Tanja Netelenbos; Ellen PA Kramer; Georgine E de Greef

doi:10.1111/trf.12979

Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor

Yavuz M. Bilgin^*, Otto J Visser, Erik A M Beckers, Liane CJ Te Boome, Cynthia Huisman, Paula F. Ypma, Alexandra J. Croockewit, Tanja Netelenbos, Ellen PA Kramer, Georgine E de Greef

^*Corresponding author for this work

Hematology - external affiliates

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Background: Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) is approved for the use of stem cell collection in patients who fail to mobilize on G-CSF. In 2009 the Stem Cell Working Party of the Dutch-Belgian Cooperative Trial group for Hematology Oncology (HOVON) composed a guideline for the use of plerixafor. According to this guideline it is recommended to add plerixafor to G-CSF in patients with circulating CD34+ cell counts of fewer than 20 × 10⁶/L on 2 consecutive days accompanied by increasing white blood cells.

Study Design and Methods: In this analysis we evaluated retrospectively the outcome of the use of this guideline in the Netherlands. In total 111 patients received plerixafor with a median one administration (range, one to four administrations). Of these patients 55.8% had non-Hodgkin lymphoma, 31.5% multiple myeloma, 8.1% Hodgkin lymphoma, and 4.5% nonhematologic malignancies.

Results: In 63.9% patients sufficient numbers of CD34+ cells were collected. In patients with multiple myeloma more successful mobilizations with plerixafor were observed compared to patients with non-Hodgkin lymphoma (71.4% vs. 61.3%). In patients with circulating CD34+ cell counts of at least 2.0 × 10⁶/L before administration of plerixafor a successful mobilization was achieved in 76.5%, and in the patients with very low (0-1 × 10⁶/L) circulating CD34+ cell counts the success rate was 44.2%.

Conclusion: Application of the HOVON guideline on the just-in-time administration of plerixafor is effective for mobilization of hematopoietic stem cells in the majority of patients. Stem cell yield in patients with non-Hodgkin lymphoma was lower compared to patients with multiple myeloma. Also patients with very low circulating CD34+ cells before addition of plerixafor might benefit from this approach.

Original language	English
Pages (from-to)	1021-1027
Number of pages	7
Journal	Transfusion
Volume	55
Issue number	5
DOIs	https://doi.org/10.1111/trf.12979
Publication status	Published - 1 May 2015

Access to Document

10.1111/trf.12979

Cite this

Bilgin, Y. M., Visser, O. J., Beckers, E. A. M., Te Boome, L. CJ., Huisman, C., Ypma, P. F., Croockewit, A. J., Netelenbos, T., Kramer, E. PA., & de Greef, G. E. (2015). Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor. Transfusion, 55(5), 1021-1027. https://doi.org/10.1111/trf.12979

@article{66c27647f8ec4be3bf8bbed3c8ff5a47,

title = "Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor",

abstract = "Background: Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) is approved for the use of stem cell collection in patients who fail to mobilize on G-CSF. In 2009 the Stem Cell Working Party of the Dutch-Belgian Cooperative Trial group for Hematology Oncology (HOVON) composed a guideline for the use of plerixafor. According to this guideline it is recommended to add plerixafor to G-CSF in patients with circulating CD34+ cell counts of fewer than 20 × 106/L on 2 consecutive days accompanied by increasing white blood cells. Study Design and Methods: In this analysis we evaluated retrospectively the outcome of the use of this guideline in the Netherlands. In total 111 patients received plerixafor with a median one administration (range, one to four administrations). Of these patients 55.8% had non-Hodgkin lymphoma, 31.5% multiple myeloma, 8.1% Hodgkin lymphoma, and 4.5% nonhematologic malignancies. Results: In 63.9% patients sufficient numbers of CD34+ cells were collected. In patients with multiple myeloma more successful mobilizations with plerixafor were observed compared to patients with non-Hodgkin lymphoma (71.4% vs. 61.3%). In patients with circulating CD34+ cell counts of at least 2.0 × 106/L before administration of plerixafor a successful mobilization was achieved in 76.5%, and in the patients with very low (0-1 × 106/L) circulating CD34+ cell counts the success rate was 44.2%. Conclusion: Application of the HOVON guideline on the just-in-time administration of plerixafor is effective for mobilization of hematopoietic stem cells in the majority of patients. Stem cell yield in patients with non-Hodgkin lymphoma was lower compared to patients with multiple myeloma. Also patients with very low circulating CD34+ cells before addition of plerixafor might benefit from this approach.",

author = "Bilgin, {Yavuz M.} and Visser, {Otto J} and Beckers, {Erik A M} and {Te Boome}, {Liane CJ} and Cynthia Huisman and Ypma, {Paula F.} and Croockewit, {Alexandra J.} and Tanja Netelenbos and Kramer, {Ellen PA} and {de Greef}, {Georgine E}",

year = "2015",

month = may,

day = "1",

doi = "10.1111/trf.12979",

language = "English",

volume = "55",

pages = "1021--1027",

journal = "Transfusion",

issn = "0041-1132",

publisher = "Wiley-Blackwell",

number = "5",

}

Bilgin, YM, Visser, OJ, Beckers, EAM, Te Boome, LCJ, Huisman, C, Ypma, PF, Croockewit, AJ, Netelenbos, T, Kramer, EPA & de Greef, GE 2015, 'Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor', Transfusion, vol. 55, no. 5, pp. 1021-1027. https://doi.org/10.1111/trf.12979

TY - JOUR

T1 - Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor

AU - Bilgin, Yavuz M.

AU - Visser, Otto J

AU - Beckers, Erik A M

AU - Te Boome, Liane CJ

AU - Huisman, Cynthia

AU - Ypma, Paula F.

AU - Croockewit, Alexandra J.

AU - Netelenbos, Tanja

AU - Kramer, Ellen PA

AU - de Greef, Georgine E

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) is approved for the use of stem cell collection in patients who fail to mobilize on G-CSF. In 2009 the Stem Cell Working Party of the Dutch-Belgian Cooperative Trial group for Hematology Oncology (HOVON) composed a guideline for the use of plerixafor. According to this guideline it is recommended to add plerixafor to G-CSF in patients with circulating CD34+ cell counts of fewer than 20 × 106/L on 2 consecutive days accompanied by increasing white blood cells. Study Design and Methods: In this analysis we evaluated retrospectively the outcome of the use of this guideline in the Netherlands. In total 111 patients received plerixafor with a median one administration (range, one to four administrations). Of these patients 55.8% had non-Hodgkin lymphoma, 31.5% multiple myeloma, 8.1% Hodgkin lymphoma, and 4.5% nonhematologic malignancies. Results: In 63.9% patients sufficient numbers of CD34+ cells were collected. In patients with multiple myeloma more successful mobilizations with plerixafor were observed compared to patients with non-Hodgkin lymphoma (71.4% vs. 61.3%). In patients with circulating CD34+ cell counts of at least 2.0 × 106/L before administration of plerixafor a successful mobilization was achieved in 76.5%, and in the patients with very low (0-1 × 106/L) circulating CD34+ cell counts the success rate was 44.2%. Conclusion: Application of the HOVON guideline on the just-in-time administration of plerixafor is effective for mobilization of hematopoietic stem cells in the majority of patients. Stem cell yield in patients with non-Hodgkin lymphoma was lower compared to patients with multiple myeloma. Also patients with very low circulating CD34+ cells before addition of plerixafor might benefit from this approach.

AB - Background: Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) is approved for the use of stem cell collection in patients who fail to mobilize on G-CSF. In 2009 the Stem Cell Working Party of the Dutch-Belgian Cooperative Trial group for Hematology Oncology (HOVON) composed a guideline for the use of plerixafor. According to this guideline it is recommended to add plerixafor to G-CSF in patients with circulating CD34+ cell counts of fewer than 20 × 106/L on 2 consecutive days accompanied by increasing white blood cells. Study Design and Methods: In this analysis we evaluated retrospectively the outcome of the use of this guideline in the Netherlands. In total 111 patients received plerixafor with a median one administration (range, one to four administrations). Of these patients 55.8% had non-Hodgkin lymphoma, 31.5% multiple myeloma, 8.1% Hodgkin lymphoma, and 4.5% nonhematologic malignancies. Results: In 63.9% patients sufficient numbers of CD34+ cells were collected. In patients with multiple myeloma more successful mobilizations with plerixafor were observed compared to patients with non-Hodgkin lymphoma (71.4% vs. 61.3%). In patients with circulating CD34+ cell counts of at least 2.0 × 106/L before administration of plerixafor a successful mobilization was achieved in 76.5%, and in the patients with very low (0-1 × 106/L) circulating CD34+ cell counts the success rate was 44.2%. Conclusion: Application of the HOVON guideline on the just-in-time administration of plerixafor is effective for mobilization of hematopoietic stem cells in the majority of patients. Stem cell yield in patients with non-Hodgkin lymphoma was lower compared to patients with multiple myeloma. Also patients with very low circulating CD34+ cells before addition of plerixafor might benefit from this approach.

UR - http://www.scopus.com/inward/record.url?scp=84929223503&partnerID=8YFLogxK

U2 - 10.1111/trf.12979

DO - 10.1111/trf.12979

M3 - Article

C2 - 25641128

AN - SCOPUS:84929223503

SN - 0041-1132

VL - 55

SP - 1021

EP - 1027

JO - Transfusion

JF - Transfusion

IS - 5

ER -

Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor

Abstract

Access to Document

Other files and links

Fingerprint

Cite this